Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.09
- Piotroski Score 2.00
- Grade Equal-Weight
- Symbol (AGLE)
- Company Aeglea BioTherapeutics, Inc.
- Price $12.01
- Changes Percentage (6.66%)
- Change $0.75
- Day Low $10.69
- Day High $12.34
- Year High $24.00
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$74.15
- Trailing P/E Ratio -0.16196898179366
- Forward P/E Ratio -0.16196898179366
- P/E Growth -0.16196898179366
- Net Income $-83,815,000
Income Statement
Quarterly
Annual
Latest News of AGLE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
NFL Week 4 winners, losers: Steelers, Eagles pay for stumbles
In NFL Week 4, the undefeated teams are down to three. Notable games include the Ravens dominating the Bills, the Vikings defeating the Packers, and the Falcons securing a victory over the Saints....
By USA Today | 13 hours ago -
Jalen Hurts shoulders blame for Philadelphia Eagles loss to Buccaneers: "I just have to play better"
Jalen Hurts and the Philadelphia Eagles faced the Tampa Bay Buccaneers in Week 4, falling short in a 33-16 loss. Despite challenges with key players missing, Hurts took responsibility for his performa...
By CBS News | 22 hours ago -
Tom Brady on Eagles' struggles vs. Bucs: 'Gotta find ways to get faster starts'
In the Eagles vs. Buccaneers game, Tom Brady emphasized the importance of a fast offensive start, which the Buccaneers executed. Brady highlighted the Eagles' struggles due to turnovers and slow start...
By Fox News | 22 hours ago